Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies

被引：115

作者：

Crawford, Yongping ^{[1
]}

Ferrara, Napoleone ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2009年 / 30卷 / 12期

关键词：

ENDOTHELIAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; MONOCLONAL-ANTIBODY; PDGF-C; PROLONGS SURVIVAL; SUPPRESSOR-CELLS; PROSTATE-CANCER; INHIBITS GROWTH; VEGF-A; METASTASIS;

D O I：

10.1016/j.tips.2009.09.004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Identification and characterization of VEGF as an important regulator of angiogenesis, and FDA approval of the first anti-angiogenic drugs, has enabled significant advances in the therapy of cancer and neovascular age-related macular degeneration. However, similar to other therapies, inherent/acquired resistance to anti-angiogenic drugs may occur in patients, leading to disease recurrence. Recent studies in several experimental models suggest that tumor and non-tumor (stromal) cell types may be involved in the reduced responsiveness to the treatments. The present review examines the role of tumor- as well as stromal cell-derived pathways involved in tumor growth and in refractoriness to anti-VEGF therapies.

引用

收藏

页码：624 / 630

页数：7

相关论文

共 100 条

[1] Lymphangiogenesis in development and human disease [J].

Alitalo, K ;

Tammela, T ;

Petrova, TV .

NATURE, 2005, 438 (7070) :946-953

[2] Paracrine Signaling by Platelet-Derived Growth Factor-CC Promotes Tumor Growth by Recruitment of Cancer-Associated Fibroblasts [J].

Anderberg, Charlotte ;

Li, Hong ;

Fredriksson, Linda ;

Andrae, Johanna ;

Betsholtz, Christer ;

Li, Xuri ;

Eriksson, Ulf ;

Pietras, Kristian .

CANCER RESEARCH, 2009, 69 (01) :369-378

[3]

[Anonymous], J CLIN ONCOL

[4] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].

Batchelor, Tracy T. ;

Sorensen, A. Gregory ;

di Tomaso, Emmanuelle ;

Zhang, Wei-Ting ;

Duda, Dan G. ;

Cohen, Kenneth S. ;

Kozak, Kevin R. ;

Cahill, Daniel P. ;

Chen, Poe-Jou ;

Zhu, Mingwang ;

Ancukiewicz, Marek ;

Mrugala, Maciej M. ;

Plotkin, Scott ;

Drappatz, Jan ;

Louis, David N. ;

Ivy, Percy ;

Scadden, David T. ;

Benner, Thomas ;

Loeffler, Jay S. ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

CANCER CELL, 2007, 11 (01) :83-95

[5] The FGF family: biology, pathophysiology and therapy [J].

Beenken, Andrew ;

Mohammadi, Moosa .

NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (03) :235-253

[6] Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].

Bergers, G ;

Song, S ;

Meyer-Morse, N ;

Bergsland, E ;

Hanahan, D .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295

[7] Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[8] Stromal fibroblasts in cancer initiation and progression [J].

Bhowmick, NA ;

Neilson, EG ;

Moses, HL .

NATURE, 2004, 432 (7015) :332-337

[9] Biological roles of fibroblast growth factor-2 [J].

Bikfalvi, A ;

Klein, S ;

Pintucci, G ;

Rifkin, DB .

ENDOCRINE REVIEWS, 1997, 18 (01) :26-45

[10] Hypoxia and cancer [J].

Brahimi-Horn, M. Christiane ;

Chiche, Johanna ;

Pouyssegur, Jacques .

JOURNAL OF MOLECULAR MEDICINE-JMM, 2007, 85 (12) :1301-1307

← 1 2 3 4 5 6 7 8 9 10 →